Stockscreener 앱 받기
1.02
4.08%
0.04
시간 외 거래:
1.03
0.01
+0.98%
전일 마감가:
$0.98
열려 있는:
$0.99
하루 거래량:
149.60K
Relative Volume:
0.84
시가총액:
$32.00M
수익:
$90,000
순이익/손실:
$-23.47M
주가수익비율:
-1.356
EPS:
-0.7522
순현금흐름:
$-22.98M
1주 성능:
-2.86%
1개월 성능:
-18.40%
6개월 성능:
-38.55%
1년 성능:
-28.67%
1일 변동 폭
$0.9801
$1.059
1주일 범위
$0.98
$1.065
52주 변동 폭
$0.952
$1.89
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
명칭
Actinium Pharmaceuticals Inc
전화
646-767-3870
주소
275 Madison Avenue, 7th Floor, New York, NY
Compare ATNM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.02 | 31.37M | 90,000 | -23.47M | -22.98M | -0.7522 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-07 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-02-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-09-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-08-25 | 개시 | B. Riley Securities | Buy |
| 2020-11-05 | 개시 | Alliance Global Partners | Buy |
| 2017-12-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-10-23 | 재개 | ROTH Capital | Buy |
| 2017-09-14 | 개시 | Maxim Group | Buy |
| 2016-08-25 | 개시 | ROTH Capital | Buy |
| 2016-02-29 | 개시 | H.C. Wainwright | Buy |
| 2015-10-15 | 개시 | FBR Capital | Outperform |
| 2014-10-01 | 개시 | MLV & Co | Buy |
| 2014-07-22 | 개시 | Canaccord Genuity | Buy |
모두보기
Actinium Pharmaceuticals Inc 주식(ATNM)의 최신 뉴스
ATNM Should I Buy - Intellectia AI
Actinium Pharmaceuticals presents expanded ATNM-400 results in NSCLC and prostate cancer - Traders Union
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC - BioWorld News
Actinium presents preclinical data on ATNM-400 for lung cancer - Investing.com UK
Actinium Pharmaceuticals (ATNM) Reveals Promising Preclinical Data for NSCLC Treatment - GuruFocus
Actinium presents preclinical data on ATNM-400 for lung cancer By Investing.com - Investing.com Australia
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer - PR Newswire
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models - PR Newswire
Actinium Pharmaceuticals (ATNM) Appoints New Chief Medical Officer - GuruFocus
Actinium Pharmaceuticals (ATNM) Unveils Key Radiochemistry Findi - GuruFocus
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development - PR Newswire
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates - PR Newswire
Actinium Pharmaceuticals Presents ATNM-400 Program Updates at SNMMI 2026 and Addresses NYSE American Listing Compliance Notice - Minichart
Actinium Pharmaceuticals Advances with Canadian Patent Allowances for ATNM - GuruFocus
Actinium Highlights New ATNM-400 Data Amid Listing Pressure - TipRanks
Actinium Pharmaceuticals, Inc. (ATNM) announced that two patent applications related to its Actimab-a and Iomab-Act projects have been granted by the Canadian Intellectual Property Office. - Bitget
Actinium Pharmaceuticalsreceives two Canadian patent allowances for Actimab-A and Iomab-Act programs - marketscreener.com
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs - PR Newswire
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice – Company AnnouncementFT.com - Financial Times
Actinium Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Actinium Pharmaceuticals (NYSE: ATNM) faces NYSE American equity shortfall and listing risk - Stock Titan
ATNM Stock Price, Quote & Chart | ACTINIUM PHARMACEUTICALS INC (NYSEARCA:ATNM) - ChartMill
Actinium Pharmaceuticals (ATNM): Modest Gain Above Support as Biotech Stock Holds Key LevelRegression Channel - The Legal Advocate
Actinium Pharmaceuticals (ATNM) Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Advances ContinueRevenue Beat Analysis - The Legal Advocate
Actinium Pharmaceuticals (ATNM) Q1 2026 Earnings: Narrower Loss Beats Expectations as Development Pipeline AdvancesEarnings Surprise Report - newsline.com
Actinium (ATNM) Delivers Q1 2026 Beat — EPS $-0.18 vs $-0.24 ExpectedMost Discussed Stocks - Newser
Actinium (ATNM) Falls -2.34% — Watching $1.19 Support 2026-05-15Viral Trade Signals - newser.com
TradingKey - TradingKey
MSN Money - MSN
Actinium: Q1 Earnings Snapshot - 10TV
[10-Q] Actinium Pharmaceuticals, Inc. Quarterly Earnings Report - Stock Titan
Actinium Pharmaceuticals Inc. (ATNM) Stock Price | Live Quotes & Charts | AMEX - StocksToTrade
Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization - Barchart.com
Actinium presents preclinical data on AML drug at AACR meeting By Investing.com - Investing.com India
Actinium Pharmaceuticals (ATNM) Unveils Promising Preclinical Fi - GuruFocus
Actinium Pharmaceuticals (ATNM) Presents Promising Data on Actim - GuruFocus
Actinium presents preclinical data on AML drug at AACR meeting - Investing.com
Actinium Pharmaceuticals presents preclinical data for ATNM-400 - Investing.com
Actinium Pharmaceuticals presents preclinical data for ATNM-400 By Investing.com - Investing.com South Africa
Dr. Electric Explains What Colorado Springs Homeowners Should Check Before Summer Electrical Demand Peaks - Weekly Voice
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting - PR Newswire
SDEV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Targeted Alpha Therapy Market Landscape Report 2026-2030: Clinical Trials Insights on 30 Drugs - GlobeNewswire Inc.
SLS vs ATNM: Which cancer stock has bigger upside ahead of fresh data reveal? - MSN
SLS Vs ATNM: Which Cancer Stock Has Bigger Upside Ahead Of Fresh Data Reveal? - Stocktwits
Actinium (ATNM) Stock: Is It a Strong Buy? (+4.00%) 2026-04-18AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
ATNM Actinium Pharmaceuticals Inc. (Delaware) gains four percent after Q4 2025 results despite slight EPS miss against analyst expectations.Financial Data - newsline.com
What are analysts saying about Actinium (ATNM) Stock | Price at $1.07, Down 0.93%Expert Stock Picks - newser.com
Actinium Pharmaceuticals Inc (ATNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):